两年前的 WWDC 2024,Craig Federighi 站在 Apple Park 的舞台上,用一种精心克制的兴奋感宣布了 Apple Intelligence。 Siri 终于要变聪明了,ChatGPT 被请进了 iOS 生态,而苹果自研的小模型会在本地安静地处理你的邮件摘要和文本改写,当时台下的开发者,仿佛看到这样一个愿景。 那一刻,苹果似乎找到了一条既能拥抱生成式 AI 又不必放弃隐私...
两年前的 WWDC 2024,Craig Federighi 站在 Apple Park 的舞台上,用一种精心克制的兴奋感宣布了 Apple Intelligence。 Siri 终于要变聪明了,ChatGPT 被请进了 iOS 生态,而苹果自研的小模型会在本地安静地处理你的邮件摘要和文本改写,当时台下的开发者,仿佛看到这样一个愿景。 那一刻,苹果似乎找到了一条既能拥抱生成式 AI 又不必放弃隐私叙事的中间路线。 两年后的今天,那条中间路线已经面目全非。 苹果 AI 负责人 John Giannandrea 被体面地「退休」,核心 AI 团队流失了十多位关键成员(其中大部分去了 Meta),Siri 的重大升级从 2025 年春天推迟到了 2026 年秋天,而苹果不得不以每年约 10 亿美元的价格向 Google 购买一个 1.2 万亿参数的 Gemini 模型来重建 Siri 的底层智能。 与此同时,Bloomberg 在本周报道了另一个重磅消息:iOS 27 将引入名为「Extensions」的新系统,允许任何第三方 AI 聊天机器人,包括 Claude、Gemini、Perplexity 等,通过 App Store 接入 Siri。 换句话说,苹果现在同时在做两件事,一边用 Google 的 Gemini 重建 Siri 的「大脑」,一边把 Siri 的「嘴巴」开放给所有竞争对手。这是一套复杂的双线并行策略,既是无奈之举,也是精明的平台算计。 但要理解它的全貌,需要先回溯过去两年苹果在 AI 领域反复摇摆的轨迹。 短短两年,Siri 转向三次 2024 年 WWDC 上亮相的 Apple Intelligence 架构曾经非常清晰:苹果自研小模型处理本地任务,当用户遇到 Siri 无法处理的复杂问题时,系统会征求用户同意后将请求转发给 ChatGPT。 这是一种「内核自研、外脑外包」的分层结构,OpenAI 扮演的是唯一的外部智能供应商。 但问题很快暴露。苹果自研模型的参数规模有限——本地模型约 30 亿参数,云端模型约 1500 亿参数,在推理能力和世界知识方面与 GPT-4 级别的模型差距明显。 更致命的是,WWDC 上演示的 Siri 高级功能,例如个人上下文理解、屏幕感知、跨应用操作,在发布时根本没有准备好。苹果一边在 iPhone 16 的营销中大...
The average one-year price target for E.ON SE (XTRA:EOAN) has been revised to 19,54 € / share. This is an increase of 10.24% from the prior estimate of 17,72 € dated February 21, 2026. The price target is an average of many targets provided by analysts. The la
The average one-year price target for E.ON SE (XTRA:EOAN) has been revised to 19,54 € / share. This is an increase of 10.24% from the prior estimate of 17,72 € dated February 21, 2026. The price target is an average of many targets provided by analysts. The la
The average one-year price target for MasTec (NYSE:MTZ) has been revised to $340.50 / share. This is an increase of 29.28% from the prior estimate of $263.39 dated February 21, 2026. The price target is an average of many targets provided by analysts. The late
The average one-year price target for MasTec (NYSE:MTZ) has been revised to $340.50 / share. This is an increase of 29.28% from the prior estimate of $263.39 dated February 21, 2026. The price target is an average of many targets provided by analysts. The late
The average one-year price target for X4 Pharmaceuticals (NasdaqCM:XFOR) has been revised to $11.90 / share. This is an increase of 25.00% from the prior estimate of $9.52 dated February 21, 2026. The price target is an average of many targets provided by anal
The average one-year price target for X4 Pharmaceuticals (NasdaqCM:XFOR) has been revised to $11.90 / share. This is an increase of 25.00% from the prior estimate of $9.52 dated February 21, 2026. The price target is an average of many targets provided by anal
The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $29.32 / share. This is an increase of 13.86% from the prior estimate of $25.76 dated February 21, 2026. The price target is an average of many targets provided by ana
The average one-year price target for Tenax Therapeutics (NasdaqCM:TENX) has been revised to $29.32 / share. This is an increase of 13.86% from the prior estimate of $25.76 dated February 21, 2026. The price target is an average of many targets provided by ana
The average one-year price target for Micron Technology (NasdaqGS:MU) has been revised to $511.82 / share. This is an increase of 36.86% from the prior estimate of $373.98 dated February 21, 2026. The price target is an average of many targets provided by anal
The average one-year price target for Micron Technology (NasdaqGS:MU) has been revised to $511.82 / share. This is an increase of 36.86% from the prior estimate of $373.98 dated February 21, 2026. The price target is an average of many targets provided by anal
The average one-year price target for Hyosung TNC (KOSE:298020) has been revised to ₩476,850.00 / share. This is an increase of 14.72% from the prior estimate of ₩415,650.00 dated February 21, 2026. The price target is an average of many targets provided by an
The average one-year price target for Hyosung TNC (KOSE:298020) has been revised to ₩476,850.00 / share. This is an increase of 14.72% from the prior estimate of ₩415,650.00 dated February 21, 2026. The price target is an average of many targets provided by an
JHVEPhoto/iStock Editorial via Getty Images It has been almost five years since I published my last article about Intuit Inc. ( INTU ), and back then I argued that Intuit was almost priced for perfection. In the conclusion I wrote: As I already spoiled above, I consider Intuit still to be overvalued. The business is great with a strong economic moat, a solid balance sheet and bargaining power over...
JHVEPhoto/iStock Editorial via Getty Images It has been almost five years since I published my last article about Intuit Inc. ( INTU ), and back then I argued that Intuit was almost priced for perfection. In the conclusion I wrote: As I already spoiled above, I consider Intuit still to be overvalued. The business is great with a strong economic moat, a solid balance sheet and bargaining power over its competitors. We can also assume double-digit growth for several years to come. Nevertheless, the current stock price is not reflecting the fundamental business in my opinion and we need at least a 20-25% pullback to make Intuit fairly valued." In the years following my article, the stock continued to increase and reached an all-time high of $813 in 2025—more than double the price it was trading for in 2021 when my last article was published. Due to the continued high valuation multiples the stock was trading for, I did not really pay closer attention to the stock. However, in the last few months, Intuit was one of the companies that sold off heavily, and the stock declined 44% from its previous 52-week and all-time high. And although a few other companies performed even worse in the last few quarters, Intuit was certainly one of the worst-performing stocks in the S&P 500. And looking back at my last article, the "Hold" rating was not so wrong after all, as the stock returned only 20% in these five years and clearly underperformed the S&P 500. I don't claim to have foreseen in 2021 that GenAI fears would crush several software companies in late 2025—including Intuit. Valuation Multiples Knowing five years in advance that GenAI fears might arise in 2025 and 2026 is certainly not one of my strengths, but I know about the risks companies trading for high valuation multiples are facing. On the one hand, we can argue that Intuit was trading for high valuation multiples for a long time, and not investing in such companies might be a mistake. On the other hand, these high valu...